The Anaesthetics team at Princess Alexandra Hospital is celebrating its top-ten ranking in a multi-centre trial involving 8880 patients published last month in the New England Journal of Medicine.
PA Hospital recruited over 280 patients to the Perioperative Administration of Dexamethasone and Infection Trial (PADDI) led by Monash University, the biggest trial in which Anaesthetics has been involved.
“Under current consensus guidelines, corticosteroids (dexamethasone) are recommended as a first line agent in the prevention of post-operative nausea and vomiting (PONV) in high risk patient cohorts,” said PA Hospital local site investigator, Associate Professor Pal Sivalingam.
“They are very effective in reducing and preventing PONV, and research has also shown that their use is associated with higher patient satisfaction post op; however, there was some concern it may increase the risk of wound infections, particularly in vulnerable patient cohorts such as patients with diabetes.”
This large-scale trial has definitively found that the use of dexamethasone during anaesthesia does not increase the risk of surgical wound infection.
“We do anticipate that the results of PADDI will impact models of care here at PAH.
“Discussions are underway to conduct a research implementation study across MSH to disseminate these results into practice.
“The PADDI results have already been reported at Surgical Grand Rounds to an audience of both Anaesthetic and Surgical colleagues, and at specialist working group meetings in the areas of ERAS and Pharmacy, “Associate Professor Pal Sivalingam said.
PAH’s final patient was recruited to the trial in July 2019, with final six-month follow-up in February 2020.
The research leader for the trial was Professor Tomás Corcoran, Director of Research in the Department of Anaesthesia and Pain Medicine, Royal Perth Hospital and Adjunct Clinical Professor in the Central Clinical School at Monash University.